1
|
Anti-Tumor Potential of IMP Dehydrogenase Inhibitors: A Century-Long Story. Cancers (Basel) 2019; 11:cancers11091346. [PMID: 31514446 PMCID: PMC6770829 DOI: 10.3390/cancers11091346] [Citation(s) in RCA: 66] [Impact Index Per Article: 13.2] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/09/2019] [Revised: 09/01/2019] [Accepted: 09/02/2019] [Indexed: 01/15/2023] Open
Abstract
The purine nucleotides ATP and GTP are essential precursors to DNA and RNA synthesis and fundamental for energy metabolism. Although de novo purine nucleotide biosynthesis is increased in highly proliferating cells, such as malignant tumors, it is not clear if this is merely a secondary manifestation of increased cell proliferation. Suggestive of a direct causative effect includes evidence that, in some cancer types, the rate-limiting enzyme in de novo GTP biosynthesis, inosine monophosphate dehydrogenase (IMPDH), is upregulated and that the IMPDH inhibitor, mycophenolic acid (MPA), possesses anti-tumor activity. However, historically, enthusiasm for employing IMPDH inhibitors in cancer treatment has been mitigated by their adverse effects at high treatment doses and variable response. Recent advances in our understanding of the mechanistic role of IMPDH in tumorigenesis and cancer progression, as well as the development of IMPDH inhibitors with selective actions on GTP synthesis, have prompted a reappraisal of targeting this enzyme for anti-cancer treatment. In this review, we summarize the history of IMPDH inhibitors, the development of new inhibitors as anti-cancer drugs, and future directions and strategies to overcome existing challenges.
Collapse
|
2
|
Doonan BB, Schaafsma E, Pinto JT, Wu JM, Hsieh TC. Application of open-access databases to determine functional connectivity between resveratrol-binding protein QR2 and colorectal carcinoma. In Vitro Cell Dev Biol Anim 2017. [PMID: 28646291 DOI: 10.1007/s11626-017-0174-x] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
Colorectal cancer (CRC) is a major cause of cancer-associated deaths worldwide. Recently, oral administration of resveratrol (trans-3,5,4'-trihydroxystilbene) has been reported to significantly reduce tumor proliferation in colorectal cancer patients, however, with little specific information on functional connections. The pathogenesis and development of colorectal cancer is a multistep process that can be categorized using three phenotypic pathways, respectively, chromosome instability (CIN), microsatellite instability (MSI), and CpG island methylator (CIMP). Targets of resveratrol, including a high-affinity binding protein, quinone reductase 2 (QR2), have been identified with little information on disease association. We hypothesize that the relationship between resveratrol and different CRC etiologies might be gleaned using publicly available databases. A web-based microarray gene expression data-mining platform, Oncomine, was selected and used to determine whether QR2 may serve as a mechanistic and functional biotarget within the various CRC etiologies. We found that QR2 messenger RNA (mRNA) is overexpressed in CRC characterized by CIN, particularly in cells showing a positive KRAS (Kirsten rat sarcoma viral oncogene homolog) mutation, as well as by the MSI but not the CIMP phenotype. Mining of Oncomine revealed an excellent correlation between QR2 mRNA expression and certain CRC etiologies. Two resveratrol-associated genes, adenomatous polyposis coli (APC) and TP53, found in CRC were further mined, using cBio portal and Colorectal Cancer Atlas which predicted a mechanistic link to exist between resveratrol→QR2/TP53→CIN. Multiple web-based data mining can provide valuable insights which may lead to hypotheses serving to guide clinical trials and design of therapies for enhanced disease prognosis and patient survival. This approach resembles a BioGPS, a capability for mining web-based databases that can elucidate the potential links between compounds to provide correlations of these interactions with specific diseases.
Collapse
Affiliation(s)
- Barbara B Doonan
- Department of Biochemistry and Molecular Biology, New York Medical College, 15 Dana Road, Valhalla, NY, 10595, USA.
| | - Evelien Schaafsma
- Department of Biochemistry and Molecular Biology, New York Medical College, 15 Dana Road, Valhalla, NY, 10595, USA
- Department of Cell Biology and Anatomy, New York Medical College, 15 Dana Road, Valhalla, NY, 10595, USA
| | - John T Pinto
- Department of Biochemistry and Molecular Biology, New York Medical College, 15 Dana Road, Valhalla, NY, 10595, USA
| | - Joseph M Wu
- Department of Biochemistry and Molecular Biology, New York Medical College, 15 Dana Road, Valhalla, NY, 10595, USA
| | - Tze-Chen Hsieh
- Department of Biochemistry and Molecular Biology, New York Medical College, 15 Dana Road, Valhalla, NY, 10595, USA
| |
Collapse
|
3
|
Abstract
Two new C-nucleoside analogues, BCX4430, an imino-C-nucleoside, and GS-6620, a phosphoramidate derivative of 1'-cyano-2'-C-methyl-4-aza-7,9-dideazaadenosine C-nucleoside, have been recently described as effective against filovirus infections (Marburg) and hepatitis C virus (HCV), respectively. The first C-nucleoside analogues were described about half a century ago. The C-nucleoside pseudouridine is a natural component of RNA, and various other C-nucleoside analogues have been reported previously for their antiviral and/or anticancer potential, the most prominent being pyrazofurin, tiazofurin, and selenazofurin. In the meantime, showdomycin, formycin, and various triazole, pyrazine, pyridine, dihydroxyphenyl, thienopyrimidine, pyrazolotriazine, and porphyrin C-nucleoside analogues have been described. It would be worth revisiting these C-nucleosides and derivatives thereof, including their phosphoramidates, for their therapeutic potential in the treatment of virus infections and, where appropriate, cancer as well.
Collapse
Affiliation(s)
- Erik De Clercq
- Rega Institute for Medical Research, KU Leuven , Minderbroedersstraat 10, B-3000 Leuven, Belgium
| |
Collapse
|
4
|
Du L, Robles AJ, King JB, Mooberry SL, Cichewicz RH. Cytotoxic dimeric epipolythiodiketopiperazines from the ascomycetous fungus Preussia typharum. JOURNAL OF NATURAL PRODUCTS 2014; 77:1459-1466. [PMID: 24893224 PMCID: PMC4073660 DOI: 10.1021/np5002253] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 03/10/2014] [Indexed: 06/03/2023]
Abstract
Two new dimeric epipolythiodiketopiperazines, preussiadins A (1) and B (2), together with two known diastereomers, leptosins C (6) and A (7), were obtained from the mycelia of a Preussia typharum isolate. The structures of the new compounds were established by spectroscopic methods, and the absolute configurations of 1 and 2 were assigned by chemical transformations and comparisons of quantum chemical ECD and VCD calculations to experimental data. Compound 1 exhibited potent cytotoxic activity in the NCI-60 cell line panel with an average LC50 value of 251 nM. Further studies demonstrated that 1 circumvents P-glycoprotein-mediated drug resistance, yet had no significant antitumor activity in a xenograft UACC-62 melanoma model.
Collapse
Affiliation(s)
- Lin Du
- Natural Products Discovery Group, Institute for Natural
Products Applications and Research Technologies, and Department of Chemistry and Biochemistry,
Stephenson Life Sciences Research Center, 101 Stephenson Parkway, University of Oklahoma, Norman, Oklahoma 73019-5251, United States
| | - Andrew J. Robles
- Department of Pharmacology, Cancer Therapy &
Research Center, and Department of Medicine, University of Texas
Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, Texas 78229, United
States
| | - Jarrod B. King
- Natural Products Discovery Group, Institute for Natural
Products Applications and Research Technologies, and Department of Chemistry and Biochemistry,
Stephenson Life Sciences Research Center, 101 Stephenson Parkway, University of Oklahoma, Norman, Oklahoma 73019-5251, United States
| | - Susan L. Mooberry
- Natural Products Discovery Group, Institute for Natural
Products Applications and Research Technologies, and Department of Chemistry and Biochemistry,
Stephenson Life Sciences Research Center, 101 Stephenson Parkway, University of Oklahoma, Norman, Oklahoma 73019-5251, United States
- Department of Pharmacology, Cancer Therapy &
Research Center, and Department of Medicine, University of Texas
Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, Texas 78229, United
States
| | - Robert H. Cichewicz
- Natural Products Discovery Group, Institute for Natural
Products Applications and Research Technologies, and Department of Chemistry and Biochemistry,
Stephenson Life Sciences Research Center, 101 Stephenson Parkway, University of Oklahoma, Norman, Oklahoma 73019-5251, United States
| |
Collapse
|
5
|
Huang H, Guzman-Perez A, Acquaviva L, Berry V, Bregman H, Dovey J, Gunaydin H, Huang X, Huang L, Saffran D, Serafino R, Schneider S, Wilson C, DiMauro EF. Structure-based design of 2-aminopyridine oxazolidinones as potent and selective tankyrase inhibitors. ACS Med Chem Lett 2013; 4:1218-23. [PMID: 24900633 DOI: 10.1021/ml4003315] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/27/2013] [Accepted: 10/21/2013] [Indexed: 11/29/2022] Open
Abstract
Aberrant activation of the Wnt pathway has been implicated in the development and formation of many cancers. TNKS inhibition has been shown to antagonize Wnt signaling via Axin stabilization in APC mutant colon cancer cell lines. We employed structure-based design to identify a series of 2-aminopyridine oxazolidinones as potent and selective TNKS inhibitors. These compounds exhibited good enzyme and cell potency as well as selectivity over other PARP isoforms. Co-crystal structures of these 2-aminopyridine oxazolidinones complexed to TNKS reveal an induced-pocket binding mode that does not involve interactions with the nicotinamide binding pocket. Oral dosing of lead compounds 3 and 4 resulted in significant effects on several Wnt-pathway biomarkers in a three day DLD-1 mouse tumor PD model.
Collapse
Affiliation(s)
- Hongbing Huang
- Departments of Medicinal Chemistry; ‡Pharmacokinetics
and Drug Metabolism; §Oncology Research; and ∥Molecular Structure, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States
| | - Angel Guzman-Perez
- Departments of Medicinal Chemistry; ‡Pharmacokinetics
and Drug Metabolism; §Oncology Research; and ∥Molecular Structure, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States
| | - Lisa Acquaviva
- Departments of Medicinal Chemistry; ‡Pharmacokinetics
and Drug Metabolism; §Oncology Research; and ∥Molecular Structure, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States
| | - Virginia Berry
- Departments of Medicinal Chemistry; ‡Pharmacokinetics
and Drug Metabolism; §Oncology Research; and ∥Molecular Structure, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States
| | - Howard Bregman
- Departments of Medicinal Chemistry; ‡Pharmacokinetics
and Drug Metabolism; §Oncology Research; and ∥Molecular Structure, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States
| | - Jennifer Dovey
- Departments of Medicinal Chemistry; ‡Pharmacokinetics
and Drug Metabolism; §Oncology Research; and ∥Molecular Structure, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States
| | - Hakan Gunaydin
- Departments of Medicinal Chemistry; ‡Pharmacokinetics
and Drug Metabolism; §Oncology Research; and ∥Molecular Structure, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States
| | - Xin Huang
- Departments of Medicinal Chemistry; ‡Pharmacokinetics
and Drug Metabolism; §Oncology Research; and ∥Molecular Structure, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States
| | - Liyue Huang
- Departments of Medicinal Chemistry; ‡Pharmacokinetics
and Drug Metabolism; §Oncology Research; and ∥Molecular Structure, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States
| | - Doug Saffran
- Departments of Medicinal Chemistry; ‡Pharmacokinetics
and Drug Metabolism; §Oncology Research; and ∥Molecular Structure, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States
| | - Randy Serafino
- Departments of Medicinal Chemistry; ‡Pharmacokinetics
and Drug Metabolism; §Oncology Research; and ∥Molecular Structure, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States
| | - Steve Schneider
- Departments of Medicinal Chemistry; ‡Pharmacokinetics
and Drug Metabolism; §Oncology Research; and ∥Molecular Structure, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States
| | - Cindy Wilson
- Departments of Medicinal Chemistry; ‡Pharmacokinetics
and Drug Metabolism; §Oncology Research; and ∥Molecular Structure, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States
| | - Erin F. DiMauro
- Departments of Medicinal Chemistry; ‡Pharmacokinetics
and Drug Metabolism; §Oncology Research; and ∥Molecular Structure, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States
| |
Collapse
|
6
|
Nicotinamide mononucleotide adenylyltransferase2 overexpression enhances colorectal cancer cell-kill by Tiazofurin. Cancer Gene Ther 2013; 20:403-12. [PMID: 23764899 DOI: 10.1038/cgt.2013.33] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2013] [Accepted: 05/19/2013] [Indexed: 11/09/2022]
Abstract
Colorectal cancer cells exhibit limited cytotoxicity towards Tiazofurin, a pro-drug metabolized by cytosolic nicotinamide mononucleotide adenylyltransferase2 (NMNAT2) to thiazole-4-carboxamide adenine dinucleotide, a potent inhibitor of inosine 5'-monophosphate dehydrogenase required for cellular guanylate synthesis. We tested the hypothesis that colorectal cancer cells that exhibit low levels of NMNAT2 and are refractory to Tiazofurin can be rendered sensitive to Tiazofurin by overexpressing NMNAT2. Transfection of hNMNAT2 resulted in a six- and threefold cytoplasmic overexpression in Caco2 and HT29 cell lines correlating with Tiazofurin-induced enhanced cell-kill. Folate receptors expressed on the cell surface of 30-50% colorectal carcinomas were exploited for cellular targeting with Tiazofurin encapsulated in folate-tethered nanoparticles. Our results indicated that in wild-type colorectal cancer cells, free Tiazofurin-induced EC50 cell-kill was 1500-2000 μM, which was reduced to 66-156 μM in hNMNAT2-overexpressed cells treated with Tiazofurin encapsulated in non-targeted nanoparticles. This efficacy was improved threefold by encapsulating Tiazofurin in folate-tethered nanoparticles to obtain an EC(50) cell-kill of 22-59 μM, an equivalent of 100-300 mg m(-2) (one-tenth of the approved dose of Tiazofurin in humans), which will result in minimal toxicity leading to cancer cell-kill. This proof-of-principle study suggests that resistance of colorectal cancer cell-kill to Tiazofurin can be overcome by sequentially overexpressing hNMNAT2 and then facilitating the uptake of Tiazofurin by folate-tethered nanoparticles, which enter cells via folate receptors.
Collapse
|
7
|
Hamilton JM, Harding MW, Genna T, Bol DK. A Phase I Dose-Ranging Study of the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of AVN944, an IMPDH Inhibitor, in Healthy Male Volunteers. J Clin Pharmacol 2013; 49:30-8. [DOI: 10.1177/0091270008325149] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
8
|
McLennan G, Bennett SL, Ju S, Babsky A, Bansal N, Shorten ML, Levitin S, Bonnac L, Panciewicz KW, Jayaram HN. Tumor response and apoptosis of N1-S1 rodent hepatomas in response to intra-arterial and intravenous benzamide riboside. Cardiovasc Intervent Radiol 2011; 35:645-52. [PMID: 21431971 DOI: 10.1007/s00270-011-0140-z] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/01/2010] [Accepted: 02/09/2011] [Indexed: 01/28/2023]
Abstract
PURPOSE Benzamide riboside (BR) induces tumor apoptosis in multiple cell lines and animals. This pilot study compares apoptosis and tumor response in rat hepatomas treated with hepatic arterial BR (IA) or intravenous (IV) BR. METHODS A total of 10(6) N1-S1 cells were placed in the left hepatic lobes of 15 Sprague-Dawley rats. After 2 weeks, BR (20 mg/kg) was infused IA (n=5) or IV (n=5). One animal in each group was excluded for technical factors, which prevented a full dose administration (1 IA and 1 IV). Five rats received saline (3 IA and 2 IV). Animals were killed after 3 weeks. Tumor volumes after IA and IV treatments were analyzed by Wilcoxon rank sum test. The percentage of tumor and normal liver apoptosis was counted by using 10 fields of TUNEL (terminal deoxynucleotidyl transferase dUTP nick-end labeling)-stained slides at 40× magnification. The percentage of apoptosis was compared between IV and IA administrations and with saline sham-treated rats by the Wilcoxon rank sum test. RESULTS Tumors were smaller after IA treatment, but this did not reach statistical significance (0.14 IA vs. 0.57 IV; P=0.138). There was much variability in percentage of apoptosis and no significant difference between IA and IV BR (44.49 vs. 1.52%; P=0.18); IA BR and saline (44.49 vs. 33.83%; P=0.66); or IV BR and saline (1.52 vs. 193%; P=0.18). CONCLUSIONS Although differences in tumor volumes did not reach statistical significance, there was a trend toward smaller tumors after IA BR than IV BR in this small pilot study. Comparisons of these treatment methods will require a larger sample size and repeat experimentation.
Collapse
Affiliation(s)
- Gordon McLennan
- Imaging Institute and Department of Bioengineering, Cleveland Clinic, 9500 Euclid Avenue ND20, Cleveland, OH 44195, USA.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Kim EJ, Love DC, Darout E, Abdo M, Rempel B, Withers SG, Rablen PR, Hanover JA, Knapp S. OGA inhibition by GlcNAc-selenazoline. Bioorg Med Chem 2010; 18:7058-64. [PMID: 20822912 DOI: 10.1016/j.bmc.2010.08.010] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2010] [Revised: 08/03/2010] [Accepted: 08/04/2010] [Indexed: 12/26/2022]
Abstract
The title compound, which differs from the powerful O-GlcNAcase (OGA) inhibitor GlcNAc-thiazoline only at the chalcogen atom (Se for S), is a much weaker inhibitor in a direct OGA assay. In human cells, however, the selenazoline shows comparable ability to induce hyper-O-GlcNAc-ylation, and the two show similar reduction of insulin-stimulated translocation of glucose transporter 4 in differentiated 3T3 adipocytes.
Collapse
Affiliation(s)
- Eun Ju Kim
- Department of Science Education-Chemistry Major, Daegu University, Gyeongbuk 712-714, Republic of Korea
| | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Affiliation(s)
- Lizbeth Hedstrom
- Department of Biology, Brandeis University, MS009, 415 South Street, Waltham, Massachusetts 02454, USA.
| |
Collapse
|
11
|
Shu Q, Nair V. Inosine monophosphate dehydrogenase (IMPDH) as a target in drug discovery. Med Res Rev 2008; 28:219-32. [PMID: 17480004 DOI: 10.1002/med.20104] [Citation(s) in RCA: 97] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
Inosine monophosphate dehydrogenase (IMPDH) is a key enzyme of de novo purine nucleotide biosynthesis and is viewed as an important target in the quest for discovery of drugs in the antiviral, antibacterial and anticancer therapeutic areas. This review focuses on the medicinal chemistry, drug discovery and chemical biology of IMPDH. Examples of IMP and cofactor site-directed inhibitors, allosteric inhibitors and isoform-selective inhibitors are presented. Comparison of IMPDHs from different organisms is also made to facilitate the design of species-selective IMPDH inhibitors for drug discovery. Special emphasis in the review is placed on IMPDH from Mycobacterium tuberculosis.
Collapse
Affiliation(s)
- Qingning Shu
- The Center for Drug Discovery and the Department of Pharmaceutical and Biomedical Sciences, R. C. Wilson PH, University of Georgia, Athens, Georgia 30602, USA
| | | |
Collapse
|
12
|
Nair V, Shu Q. Inosine monophosphate dehydrogenase as a probe in antiviral drug discovery. Antivir Chem Chemother 2008; 18:245-58. [PMID: 18046958 DOI: 10.1177/095632020701800501] [Citation(s) in RCA: 45] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
Inosine monophosphate (IMP) dehydrogenase (IMPDH) is a significant enzyme in the purine nucleotide biosynthetic pathway. IMPDH is viewed as an important biological target in the quest for drugs in the antiviral therapeutic area. This review article is focused on the chemistry and biology of IMPDH inhibitors and the use of IMPDH inhibition data as a probe in antiviral drug discovery. Examples of both inosine 5' monophosphate and NAD+ site-directed inhibitors are presented. Correlation of antiviral activities with IMPDH inhibition is discussed.
Collapse
Affiliation(s)
- Vasu Nair
- The Center for Drug Discovery, Department of Pharmaceutical and Biomedical Sciences, The University of Georgia, Athens, GA, USA.
| | | |
Collapse
|
13
|
McLennan G, Cressman ENK, Xu Y, Zhang D, Jagtap MR, Jayaram HN. The effect of benzamide riboside on the VX2 model of liver cancer in rabbits. J Vasc Interv Radiol 2006; 16:1499-504. [PMID: 16319157 DOI: 10.1097/01.rvi.0000185416.08458.01] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023] Open
Abstract
PURPOSE Benzamide riboside (BR) causes apoptosis in multiple tumor cell lines by its inhibition of guanylate biosynthesis. The purpose of this study was to determine the feasibility of the use of BR as a therapeutic agent for hepatic artery infusional cancer therapy in a rabbit VX2 papilloma tumor model. MATERIALS AND METHODS VX2 tumor was implanted into the left lobe of the liver of each of 14 New Zealand White rabbits and allowed to grow for 19 days +/- 3. The proper hepatic artery was selected with a 3-F catheter via right femoral cutdown. The animals were treated with one infusion of 0.9% saline solution (n = 2), 1 mg/kg BR (n = 4), 5 mg/kg BR (n = 4), or 10 mg/kg BR (n = 4). One animal treated with 5 mg/kg BR did not develop tumor. Livers were explanted after 24 hours and sectioned through the tumor. Terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) staining was performed on the slides and they were imaged at a magnification of 40 to detect apoptotic cells. Four random fields were obtained from each slide and the percentage of apoptotic cells was calculated by dividing the number of TUNEL-positive cells by the total number of cells. Sections of liver not involved with tumor were seen in five animals: two that received 1 mg/kg BR, one that received 5 mg/kg, and two that received 10 mg/kg. RESULTS The mean tumor apoptosis rates were 1.3% with saline solution treatment, 44.8% with 1 mg/kg BR, 52.7% with 5 mg/kg BR, and 70.7% with 10 mg/kg BR. The mean tumor apoptosis in treated animals was significantly greater than in control animals (P = .003) and mean tumor apoptosis was significantly greater with 10 mg/kg BR than with 1 mg/kg BR (P = .03). There were no apoptotic cells in normal liver treated with 1 mg/kg BR or 10 mg/kg BR. The animal that received 5 mg/kg BR exhibited 10.5% apoptotic cells in the field examined (eight of 76 cells). In the animal treated with 5 mg/kg BR but in which tumor did not grow, only one of 76 cells (0.65%) was apoptotic in the area of the injection scar. CONCLUSION BR induces apoptosis in VX2 tumor in the rabbit model with minimal apoptosis in normal liver.
Collapse
Affiliation(s)
- Gordon McLennan
- Department of Radiology, Indiana University Medical Center, Indiana University/Purdue University at Indianapolis, Indianapolis, Indiana, USA.
| | | | | | | | | | | |
Collapse
|
14
|
Floryk D, Huberman E. Mycophenolic acid-induced replication arrest, differentiation markers and cell death of androgen-independent prostate cancer cells DU145. Cancer Lett 2006; 231:20-9. [PMID: 16356827 DOI: 10.1016/j.canlet.2005.01.006] [Citation(s) in RCA: 41] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2004] [Revised: 12/31/2004] [Accepted: 01/07/2005] [Indexed: 01/02/2023]
Abstract
Inosine 5'-monophosphate dehydrogenase inhibitors including mycophenolic acid (MPA) are effective inducers of terminal differentiation in a variety of distinct human tumor cell types. Here, we report that MPA also induces such a differentiation in the androgen-independent prostate cancer derived cell line DU145. MPA evoked replication arrest and accumulation of the DU145 cells in the S-phase of the cell cycle. The inhibitor also induced the expression of CD55, clusterin, granulophysin, glucose-regulated protein 78, vasoactive intestinal polypeptide and prostate-specific transglutaminase, which are differentiation markers associated with the phenotype of normal prostate cells. We suggest that inosine 5'-monophosphate dehydrogenase inhibitors, which are already used for the treatment of other diseases, may be used as potential differentiation therapy drugs to control prostate cancer.
Collapse
Affiliation(s)
- Daniel Floryk
- Gene Expression Group-Energy Systems Division, Argonne National Laboratory, 9700 S Cass Ave, Bldg 202, Argonne, IL 60439, USA
| | | |
Collapse
|
15
|
Abstract
Thirty years after its synthesis, the mechanism of action of ribavirin is still not completely understood. Although much is known about the metabolism and biochemical effects of ribavirin in human cells, there is still much to be learned about the precise mechanism of action of ribavirin with the various viruses. New information about its ability to induce mutations in viral genomes has led to new questions about its mechanism of action. There is considerable evidence that indicates that ribavirin triphosphate (RTP) can interact with the various viral RNA polymerases, and it seems likely that this interaction is important to the mechanism of action of ribavirin. It seems likely that ribavirin will not have one universal mechanism of action, but will inhibit different viruses in different ways. In some cases, inhibition of IMP dehydrogenase may be sufficient for antiviral activity. Whereas, in other cases, inhibition of viral RNA polymerases by RTP may be more important. It is also likely that RTP will interact with the different viral RNA polymerases in different ways leading to different mechanisms of actions. More comprehensive studies are needed that address all aspects of ribavirin metabolism and biochemical actions to gain a thorough understanding of the activity of this agent. Finally, the differences in the metabolism and biochemical actions of ribavirin, selenazofurin, and tiazofurin indicate that small structural changes can have profound effects on biological activity. This observation is well known by investigators familiar with nucleoside analogs, but indicate that one should not assume that agents of similar structure have identical activities.
Collapse
Affiliation(s)
- William B Parker
- Southern Research Institute, 2000 Ninth Avenue South, Birmingham, AL 35205, USA.
| |
Collapse
|
16
|
Damaraju VL, Visser F, Zhang J, Mowles D, Ng AML, Young JD, Jayaram HN, Cass CE. Role of human nucleoside transporters in the cellular uptake of two inhibitors of IMP dehydrogenase, tiazofurin and benzamide riboside. Mol Pharmacol 2004; 67:273-9. [PMID: 15486050 DOI: 10.1124/mol.104.004408] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
Benzamide riboside (BR) and tiazofurin (TR) are converted to analogs of NAD that inhibit IMP dehydrogenase (IMPDH), resulting in cellular depletion of GTP and dGTP and inhibition of proliferation. The current work was undertaken to identify the human nucleoside transporters involved in cellular uptake of BR and TR and to evaluate their role in cytotoxicity. Transportability was examined in Xenopus laevis oocytes and Saccharomyces cerevisiae that produced individual recombinant human concentrative nucleoside transporter (CNT) and equilibrative nucleoside transporter (ENT) types (hENT1, hENT2, hCNT1, hCNT2, or hCNT3). TR was a better permeant than BR with a rank order of transportability in oocytes of hCNT3 >> hENT1 > hENT2 > hCNT2 >> hCNT1. The concentration dependence of inhibition of [(3)H]uridine transport in S. cerevisiae by TR exhibited lower K(i) values than BR: hCNT3 (5.4 versus 226 microM), hENT2 (16 versus 271 microM), hENT1 (57 versus 168 microM), and hCNT1 (221 versus 220 microM). In cytotoxicity experiments, BR was more cytotoxic than TR to cells that were either nucleoside transport-defective or -competent, and transport-competent cells were more sensitive to both drugs. Exposure to nitrobenzylmercaptopurine ribonucleoside conferred resistance to BR and TR cytotoxicity to hENT1-containing CEM cells, thereby demonstrating the importance of transport capacity for manifestation of cytoxicity. A breast cancer cell line with mutant p53 exhibited 9-fold higher sensitivity to BR than the otherwise similar cell line with wild-type p53, suggesting that cells with mutant p53 may be potential targets for IMPDH inhibitors. Further studies are warranted to determine whether this finding can be generalized to other cell types.
Collapse
Affiliation(s)
- Vijaya L Damaraju
- Department of Oncology, Cross Cancer Institute, 11560 University Avenue, Edmonton, Alberta T6G 1Z2, Canada
| | | | | | | | | | | | | | | |
Collapse
|
17
|
Christopherson RI, Lyons SD, Wilson PK. Inhibitors of de novo nucleotide biosynthesis as drugs. Acc Chem Res 2002; 35:961-71. [PMID: 12437321 DOI: 10.1021/ar0000509] [Citation(s) in RCA: 131] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Potent inhibitors of enzymes catalyzing reactions in the de novo pathways for biosynthesis of purine and pyrimidine nucleotides are synthetic or natural-product analogues of pathway intermediates or, more recently, inhibitors rationally designed from a knowledge of the catalytic mechanism. Such inhibitors may be effective drugs against cancer, inflammatory disorders, or various infections. For human cancer, the purine pathway may be a better target for inhibition than the pyrimidine pathway, where toxic side effects are more apparent. Drugs such as methotrexate and 6-mercaptopurine have multiple sites of action, making it difficult to quantitatively predict their effects upon cells. Rational design of inhibitors based upon the X-ray structure of the target enzyme has the prospect of yielding drugs with only one site of action in human cells. Such a drug is VX-497, a potent inhibitor of the purine enzyme, IMP dehydrogenase.
Collapse
Affiliation(s)
- Richard I Christopherson
- School of Molecular and Microbial Biosciences, University of Sydney, Sydney, NSW, 2006, Australia.
| | | | | |
Collapse
|
18
|
Stuyver LJ, Lostia S, Patterson SE, Clark JL, Watanabe KA, Otto MJ, Pankiewicz KW. Inhibitors of the IMPDH enzyme as potential anti-bovine viral diarrhoea virus agents. Antivir Chem Chemother 2002; 13:345-52. [PMID: 12718406 DOI: 10.1177/095632020201300602] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
Ribavirin and mycophenolic acid (MPA) are known inhibitors of the IMPDH enzyme (E.C. 1.1.1.205). This enzyme catalyzes the conversion of inosine monophosphate to xanthine monophosphate, leading eventually to a decrease in the intracellular level of GTP and dGTP. The antiviral effect against bovine viral diarrhoea virus (BVDV) of 15 analogues related to MPA was determined. MDBK cells were infected with the cytopathic strain of BVDV in presence or absence of test compounds. Viral RNA was extracted from the cell supernatant fluids and quantified by RT-PCR. Ribavirin showed a potent antiviral effect against BVDV with 90% effective concentration (EC90) of 4 microM. MPA along with several analogues, including both its corresponding aldehyde and alcohol, and modifications in the length of the side chain (C2- and C4-derivatives) were tested. We have identified previously unreported IMPDH inhibitors that have potent anti-BVDV activity, namely: C6-MPAlc (5), C6-MPA-Me (7), C4-MPAlc (8), C4-MPA (10) and C2-MAD (20). Most of these compounds inhibited the IMPDH enzyme in the nanomolar range (4-800 nM) in cell-free assays. Some compounds, such as mizoribine, which is a potent inhibitor of IMPDH in vitro (enzyme 50% inhibitory concentration IC50=4 nM), had no detectable anti-BVDV activity up to 100 microM. The compounds were essentially non-toxic to a confluent monolayer of MDBK cells. However, in exponentially growing cells, they showed minimal toxicity at 100 microM over a 24 h period, but the toxicity was more pronounced after 3 days [50% cytotoxic concentration (CC50) value ranged from 5 to 30 microM].
Collapse
|
19
|
Yalowitz JA, Pankiewicz K, Patterson SE, Jayaram HN. Cytotoxicity and cellular differentiation activity of methylenebis(phosphonate) analogs of tiazofurin and mycophenolic acid adenine dinucleotide in human cancer cell lines. Cancer Lett 2002; 181:31-8. [PMID: 12430176 DOI: 10.1016/s0304-3835(02)00045-9] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
Mycophenolic acid (MPA) is a fungally-derived inhibitor of inosine 5'-monophosphate dehydrogenase (IMPDH). MPA binds IMPDH at the nicotinamide sub-site of the NAD cofactor binding domain leaving the adenosine sub-site empty. In order to improve the binding affinity we synthesized MPA analogs by linking adenosine 5'-methylenebis(phosphonate) with mycophenolic alcohols containing 2-, 4-, and 6-carbon atoms in their aliphatic side chain. Adenine dinucleotide analogs of tiazofurin, selenazofurin and benzamide riboside were synthesized as P1, P2-disubstituted pyrophosphates. Cytotoxicity of each analog was examined in human colon adenocarcinoma HT-29 and erythroleukemia K562 cells, and induction of differentiation in K562 cells by these agents was determined. Mycophenolic acid is currently used as an immunosuppressant but its anticancer action is limited by inactivation due to rapid glucuronidation. The new analogs show resistance to metabolism to inactive species and exhibit enhanced cytotoxicity in tumor cell lines, and therefore could be useful as anticancer agents.
Collapse
Affiliation(s)
- Joel A Yalowitz
- Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, 635 Barnhill Drive, MS407, Indianapolis, IN 46202-5122, USA
| | | | | | | |
Collapse
|
20
|
Rabow AA, Shoemaker RH, Sausville EA, Covell DG. Mining the National Cancer Institute's tumor-screening database: identification of compounds with similar cellular activities. J Med Chem 2002; 45:818-40. [PMID: 11831894 DOI: 10.1021/jm010385b] [Citation(s) in RCA: 108] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
In an effort to enhance access to information available in the National Cancer Institute's (NCI) anticancer drug-screening database, a new suite of Internet accessible (http://spheroid. ncifcrf.gov) computational tools has been assembled for self-organizing map-based (SOM) cluster analysis and data visualization. A range of analysis questions were initially addressed to evaluate improvements in SOM cluster quality based on the data-conditioning procedures of Z-score normalization, capping, and treatment of missing data as well as completeness of drug cell-screening data. These studies established a foundation for SOM cluster analysis of the complete set of NCI's publicly available antitumor drug-screening data. This analysis identified relationships between chemotypes of screened agents and their effect on four major classes of cellular activities: mitosis, nucleic acid synthesis, membrane transport and integrity, and phosphatase- and kinase-mediated cell cycle regulation. Validations of these cellular activities, obtained from literature sources, found (i) strong evidence supporting within cluster memberships and shared cellular activity, (ii) indications of compound selectivity between various types of cellular activity, and (iii) strengths and weaknesses of the NCI's antitumor drug screen data for assigning compounds to these classes of cellular activity. Subsequent analyses of averaged responses within these tumor panel types find a strong dependence on chemotype for coherence among cellular response patterns. The advantages of a global analysis of the complete screening data set are discussed.
Collapse
Affiliation(s)
- Alfred A Rabow
- Science Applications International Corporation and Developmental Therapeutics Program, DCTD, National Cancer Institute/NIH, Frederick, MD 21702, USA.
| | | | | | | |
Collapse
|
21
|
Grusch M, Polgar D, Gfatter S, Leuhuber K, Huettenbrenner S, Leisser C, Fuhrmann G, Kassie F, Steinkellner H, Smid K, Peters GJ, Jayaram HN, Klepal W, Szekeres T, Knasmüller S, Krupitza G. Maintenance of ATP favours apoptosis over necrosis triggered by benzamide riboside. Cell Death Differ 2002; 9:169-78. [PMID: 11840167 DOI: 10.1038/sj.cdd.4400937] [Citation(s) in RCA: 56] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/06/2001] [Revised: 07/31/2001] [Accepted: 08/01/2001] [Indexed: 11/09/2022] Open
Abstract
A new synthetic drug, benzamide riboside (BR) exhibited strong oncolytic activity against leukemic cells in the 5-10 microM range. Higher BR-concentrations (20 microM) predominantly induced necrosis which correlated with DNA strand breaks and subsequent depletion of ATP- and dATP levels. Replenishment of the ATP pool by addition of adenosine prevented necrosis and favoured apoptosis. This effect was not a pecularity of BR-treatment, but was reproduced with high concentrations of all trans-retinoic acid (120 microM) and cyanide (20 mM). Glucose was also capable to suppress necrosis and to favour apoptosis of HL-60 cells, which had been treated with necrotic doses of BR and cyanide. Apoptosis eliminates unwanted cells without affecting the microenvironment, whereas necrosis causes severe inflammation of surrounding tissues due to spillage of cell fluids into the peri-cellular space. Thus, the monitoring and maintenance of cellular energy pools during therapeutic drug treatment may help to minimize nonspecific side effects and to improve attempted drug effects.
Collapse
Affiliation(s)
- M Grusch
- Institute of Clinical Pathology, University of Vienna, Austria
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Mugesh G, du Mont WW, Sies H. Chemistry of biologically important synthetic organoselenium compounds. Chem Rev 2001; 101:2125-79. [PMID: 11710243 DOI: 10.1021/cr000426w] [Citation(s) in RCA: 1244] [Impact Index Per Article: 54.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Affiliation(s)
- G Mugesh
- Institut für Anorganische und Analytische Chemie, Technischen Universität, Postfach 3329, D-38023 Braunschweig, Germany
| | | | | |
Collapse
|
23
|
Rauko P, Novotny L, Dovinova I, Hunakova L, Szekeres T, Jayaram HN. Antitumor activity of benzamide riboside and its combination with cisplatin and staurosporine. Eur J Pharm Sci 2001; 12:387-94. [PMID: 11231105 DOI: 10.1016/s0928-0987(00)00180-9] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
Benzamide riboside (BR), a new synthetic nucleoside analogue, has demonstrated a potent cytotoxic activity in murine leukemia in vitro. The purpose of the present investigation was to examine the antitumor activity of BR in mice bearing leukemia L1210. The results revealed that BR possesses a potent antitumor activity in vivo. It increases life-span of mice with leukemia. Synergistic cytotoxicity of BR with select DNA damaging agents, cisplatin (cis-Pt) and staurosporine (STP) was examined in MTT chemosensitivity assay, FACS analyses and apoptotic DNA fragmentation on L1210 cells in culture. A simultaneous treatment of leukemia L1210 cells with the combination of BR and STP resulted in synergistic cytotoxicity that correlated with increased apoptotic activity in those cells. On the other hand, treatment of L1210 cells with combination of BR and cis-Pt resulted in antagonistic cytotoxic effect. Finally, to elucidate the synergistic effect of BR and STP in inducing apoptosis, the attention was directed to the activation of cell death processes through various cell cycle signals. This is the first report describing in vivo antitumor activity of BR and its utilization in combination chemotherapy.
Collapse
Affiliation(s)
- P Rauko
- Cancer Research Institute, Slovak Academy of Sciences, Vlarska 7, SK-833 91 Bratislava, Slovak Republic
| | | | | | | | | | | |
Collapse
|
24
|
Goldstein BM, Colby TD. Conformational constraints in NAD analogs: implications for dehydrogenase binding and specificity. ADVANCES IN ENZYME REGULATION 2000; 40:405-26. [PMID: 10828360 DOI: 10.1016/s0065-2571(99)00056-4] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Affiliation(s)
- B M Goldstein
- Department of Biochemistry and Biophysics, University of Rochester, Rochester, NY 14642, USA
| | | |
Collapse
|
25
|
Franchetti P, Marchetti S, Cappellacci L, Jayaram HN, Yalowitz JA, Goldstein BM, Barascut JL, Dukhan D, Imbach JL, Grifantini M. Synthesis, conformational analysis, and biological activity of C-thioribonucleosides related to tiazofurin. J Med Chem 2000; 43:1264-70. [PMID: 10753464 DOI: 10.1021/jm990257b] [Citation(s) in RCA: 33] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
The syntheses of furanthiofurin [5beta-D-(4'-thioribofuranosyl)furan-3-carboxamide, 1] and thiophenthiofurin [5beta-D-(4'-thioribofuranosyl)thiophene-3-carboxamide, 2], two C-thioribonucleoside analogues of tiazofurin, are described. Direct trifluoroacetic acid-catalyzed C-glycosylation of ethyl furan-3-carboxylate with 1-O-acetyl-2,3,5-tri-O-benzyl-4-thio-D-ribofuranose gave 2- and 5-glycosylated regioisomers, as a mixture of alpha and beta anomers. Ethyl 5-(2,3,5-tri-O-benzyl)-beta-D-(4'-thioribofuranosyl)furan-3-carboxylate (6beta) was debenzylated and then converted into the corresponding amide (furanthiofurin) by reaction with ammonium hydroxide. A similar C-glycosylation of ethyl thiophene-3-carboxylate with 1,2,3,5-tetra-O-acetyl-4-thio-D-ribofuranose catalyzed by stannic chloride afforded an anomeric mixture of 2- and 5-glycosylated regioisomers. Deacetylation of ethyl 5-(2,3,5-tri-O-acetyl)-beta-D-(4'-thioribofuranosyl)thiophene-3-carboxylate (13beta) with methanolic ammonia and treatment of the ethyl ester with ammonium hydroxide gave thiophenthiofurin. The glycosylation site and anomeric configuration were established by (1)H NMR spectroscopy. Thiophenthiofurin was found to be cytotoxic in vitro toward human myelogenous leukemia K562, albeit 39-fold less than thiophenfurin, while furanthiofurin proved to be inactive. K562 cells incubated with thiophenthiofurin resulted in inhibition of inosine 5'-monophosphate dehydrogenase (IMPDH) and an increase in IMP pools with a concurrent decrease in GTP levels. From computational studies it was deduced that, among the C-nucleoside analogues of tiazofurin, activity requires an electrophilic sulfur adjacent to the C-glycosidic bond and an energetically favorable conformer around chi = 0 degrees. Among these, the more constrained (least flexible) compounds (tiazofurin and thiophenfurin) are more active than the less constrained thiophenthiofurin. Those compounds which contain a nucleophilic oxygen in place of the thiazole or thiophene (oxazofurin, furanfurin, and furanthiofurin) show the least activity.
Collapse
Affiliation(s)
- P Franchetti
- Dipartimento di Scienze Chimiche, Università di Camerino, Via S. Agostino, 1, 62032 Camerino, Italy.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
26
|
Maeda H, Kambe N, Sonoda N, Fujiwara SI, Shin-ike T. Synthesis of 1,3-selenazoles and 2-imidazolin-5-selones from isoselenocyanates and isocyanides. Tetrahedron 1997. [DOI: 10.1016/s0040-4020(97)00931-9] [Citation(s) in RCA: 32] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
27
|
Pankiewicz KW, Lesiak K, Zatorski A, Goldstein BM, Carr SF, Sochacki M, Majumdar A, Seidman M, Watanabe KA. The practical synthesis of a methylenebisphosphonate analogue of benzamide adenine dinucleotide: inhibition of human inosine monophosphate dehydrogenase (type I and II). J Med Chem 1997; 40:1287-91. [PMID: 9111303 DOI: 10.1021/jm960641y] [Citation(s) in RCA: 22] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
beta-Methylene-BAD (8), a nonhydrolyzable analogue of benzamide adenine dinucleotide (BAD), was synthesized as potential inhibitor of human inosine monophosphate dehydrogenase (IMPDH). Treatment of 2',3'-O-isopropylideneadenosine 5'-methylenebisphosphonate (15) with DCC afforded P1,P4-bis(2',3'-O-isopropylideneadenosine) 5'-P1,P2:P3,P4-dimethylenetetrakisphosphonate (17). This compound was further converted with DCC to an active intermediate 18 which upon reaction with 3-(2',3'-O-isopropylidene-beta-D-ribofuranosyl)benzamide (19) gave, after hydrolysis and deisopropylidenation, the desired beta-methylene-BAD (8) in 95% yield. In a similar manner, treatment of 18 with 2',3'-O-isopropylidenetiazofurin (21) followed by hydrolysis and deprotection afforded beta-methylene-TAD (5) in 91% yield. Compound 8 (IC50 = 0.665 microM) was found to be a 6-8 times less potent inhibitor of IMPDH than 5 (IC50 = 0.107 microM) and was almost equally potent against IMPDH type I and type II. Although TAD and beta-methylene-TAD were bound by LADH with the same affinity, the binding affinity of 8 toward LADH (Ki = 333 microM) was found to be 50-fold lower than that of the parent pyrophosphate 7 (Ki = 6.3 microM).
Collapse
Affiliation(s)
- K W Pankiewicz
- Codon Pharmaceuticals, Inc., Gaithersburg, Maryland 20877, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
28
|
Zatorski A, Watanabe KA, Carr SF, Goldstein BM, Pankiewicz KW. Chemical synthesis of benzamide adenine dinucleotide: inhibition of inosine monophosphate dehydrogenase (types I and II). J Med Chem 1996; 39:2422-6. [PMID: 8691436 DOI: 10.1021/jm9601415] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
Treatment of 3-(2,3-O-isopropylidene-beta-D-ribofuranosyl)benzamide (6) with POCl3 in (EtO)3-PO afforded only little phosphorylation product (8, 5%), but the major product was 5'-chlorobenzamide riboside (7, 85%). Reaction of 6 with 2-cyanoethyl N,N-diisopropylchlorophosphoramidite followed by 2-cyanoethanol/tetrazole treatment and oxidation with tert-butyl peroxide gave a 1:1 mixture of the desired 5'-O-bis(2-cyanoethyl) phosphate 9 and the chloro derivative 7. This mixture was treated with methanolic ammonia and partitioned between CHCl3 and water. The 2',3'-O-isopropylidenebenzamide mononucleotide (8) was obtained in 21.2% overall yield from the aqueous layer. Compound 8 was then converted into the corresponding imidazolide 11b which, upon coupling with 2',3'-O-acetonide of AMP, afforded the acetonide of benzamide adenine dinucleotide (15) in 94% yield together with small amounts of symmetrical pyrophosphates P1,P2-bis(2',3'-O-isopropylideneadenosin-5'-yl)pyrophosphate (13, 3%) and P1,P2-bis(2',3'-O-isopropylidene-3-(carbamoylphenyl)-5'-ribosyl)py rophosphate (14, 2%). Deprotection of 15 with Dowex 50/H+ in water afforded the desired benzamide adenine dinucleotide (BAD) in 93% yield. BAD inhibits inosine monophosphate dehydrogenase type I (IC50 = 0.78 microM) and type II (IC50 = 0.88 microM) with same degree of potency.
Collapse
Affiliation(s)
- A Zatorski
- OncorPharm, Inc., Gaithersburg, Maryland 20877, USA
| | | | | | | | | |
Collapse
|